Press Releases

GW Pharmaceuticals to Report Interim 2013 Results and Host Conference Call on 3 June, 2013

14 May 2013

London, UK, 14 May 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics f... more

GW Pharmaceuticals plc Announces the Closing of its Initial Public Offering on the Nasdaq Global Market

8 May 2013

London, UK, 8 May 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics fr... more

GW Pharmaceuticals plc Announces Sativex® Commercialization Approval in Italy

7 May 2013

London, UK, 7 May 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics fr... more

GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global Market

1 May 2013

GW announced today the pricing of its initial public offering of 3,500,000 American Depository Shares (“ADSs”) on the NASDAQ Global Market at a price of $8.90 per ADS.... more

GW Pharmaceuticals Announces US Patent Allowance for SATIVEX® Formulation Spray Device

22 April 2013

Follows Recent Notice of Allowance for Sublingual Delivery of Sativex Formulation Patent-... more

GW Pharmaceuticals Files Updated Amendment to Registration Statement for NASDAQ Global Market Listing

18 April 2013

Porton Down, UK, 18 April 2013: GW Pharmaceuticals plc (AIM: GWP or the “Company”) hereby provides notification that, further to the announcement on 19 March 2013 of the filing of a registration state... more

Results of General Meeting

12 April 2013

Porton Down, UK, 12 April 2013: GW Pharmaceuticals plc (AIM: GWP or the “Company”) hereby provides notification that, at the General Meeting of Company held earlier today, all the resolutions set out ... more

GW Pharmaceuticals’ cannabinoid-medicine Sativex® moved to Schedule 4 of UK Drugs Act

10 April 2013

Porton Down, UK; 10 April 2013: GW Pharmaceuticals, the biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product pla... more

GW Pharmaceuticals Announces New US Patent Allowance

3 April 2013

Porton Down, UK; 3 April 2013: GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid... more

GW Pharmaceuticals Files Registration Statement for NASDAQ Global Market Listing

19 March 2013

Porton Down, UK, 19 March 2013: GW Pharmaceuticals plc (AIM: GWP, "GW" or the “Company”), the biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from i... more

Update on Sativex® in Germany

19 March 2013

Porton Down, UK, 19 March 2013: GW Pharmaceuticals plc (AIM: GWP, “GW”), the specialty pharmaceutical company focused on cannabinoid science, today provides an update on pricing negotiations in German... more

GW Appoints Stephen D. Schultz as Vice President of Investor Relations

19 March 2013

Porton Down, UK; March 19 2013: GW Pharmaceuticals plc (AIM:GWP) today announced the appointment of Stephen D. Schultz to the new role of Vice President, Investor Relations. Mr. Schultz will be based ... more

GW Appoints Cabot Brown as a Non-Executive Director

19 February 2013

Porton Down, UK; February 19 2013: GW Pharmaceuticals plc (AIM:GWP) today announces the appointment of Cabot Brown as a non-executive director with immediate effect. Mr Brown will sit on the Nominatio... more